Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Degradation of GM1 ganglioside
- Clinical progression of Tay-Sachs and Sandhoff (1)
- 3 products needed to hydrolyze GM2 ganglioside
- Lysosomal GM2 ganglioside degradation
- Common used substrates: MUG, MUGS
- Structure-function relationships questions
- Use of mutations causing TSD in Hex A research
- The B1-variant of TSD
- Alpha-Arg-178 and beta-Arg-211: substrate binding
- The crystal structure of beta-Hex B isozyme
- A stereo-view on the active site
- The crystal structure of GM2-activator protein
- Space-filling model of the GM2 activator
- Model of the Hex A/activator/GM2 complex
- Alpha-active site with bound GM2 ganglioside
- The structures of alpha and beta subunits of Hex A
- Do Arg424 and -SO4 interact in MUGS?
- The importance of IPV/GSEP loops of Hex A
- The Hex A isozyme hydrolyzes GM2
- Hex S can not hydrolyze GM2
- Effect of beta-P504S on GM2 hydrolysis by Hex A
- Milder forms of GM2 gangliosidosis
- Subacute/juvenile GM2-ganglisidosis
- Chronic/adult GM2-gangliosidosis
- The critical threshold hypothesis
- Biosynthesis and intracellular trafficking
- Biosynthetic and endocytotic pathways
- Therapeutic approaches
- Treatment of LSD, particularly Gaucher disease
- Evaluation of two small molecule-based therapies
- SRT and EET
- Chaperone therapy targets the ER QC system
- The ER quality control system and the ERAD
- Involvement of ERAD in the disease process
- Model of Hex A/GM2 activator/GM2 ganglioside
- The ATSD mutation decreases protein stability
- ERAD: ER associated degradation
- Unaffected cells
- ATSD cells
- ATSD cells and inhibitor
- NGT: a pharmacological chaperone for ATSD
- Interactions of NGT in the beta subunit
- NGT increases the heat stability of ATSD Hex A
- Tay-Sachs cells grown in the presence of NGT
- Increased Hex A (MUGS) activity is lysosomal
- Summary
Topics Covered
- GM2 gangliosidosis: the disease and the associated system of beta-hexosaminidase isozymes
- Structure-function relationships
- What have naturally occurring mutations told us?
- Why is dimerization necessary for activity if both subunits have active sites?
- What is the basis for the substrate-specificity differences between the active sites of the two subunits?
- Why can only heterodimeric hexosaminidase A hydrolyze GM2 ganglioside?
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mahuran, D. (2016, January 9). GM2 gangliosidoses [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/MGZQ4484.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Don Mahuran has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neurology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Don Mahuran,
a senior scientist at The Hospital for Sick Children in Toronto,
Ontario Canada and professor in
the Department of Laboratory Medicine and Pathobiology at the University of Toronto.
My topic is GM2 Gangliosidosis,
which is actually a family of very similar diseases known as Tay-Sachs,
Sandhoff, and the AB-variant form.
These diseases all are caused by the storage of
this rather complex acidic glycolipid known as GM2 ganglioside
in the lysosomes of mainly neuronal cells.
One of the more obvious effects of this storage,
is the development of this retinal cherry-red spot you see on
the right which was noted in Tay-Sachs patients as early as 1880.
0:43
Gangliosides are broken down in lysosomes by a series of
sequential cleavage steps removing each of the terminal non-reducing sugars in order.
These reactions are carried out by specific lysosomal exo-glycosidases.
If any one of these exo-glycosidases is deficient,
the degradation stops at that point and can go no further.
As an example, we're looking here at
GM1 ganglioside which is one of the major brain gangliosides.
You can see the chemical structure is being represented by these geometric shapes.
Now GM1 is actually stored in two diseases known as
GM1 ganglisidosis or Morquio type B which differ really
only in phenotype because they are both caused by a deficiency of beta galactosidase
which would normally remove the terminal galactose residue to produce GM2 ganglioside,
which is stored in Tay-Sachs and Sandhoff disease because of
a lack of beta-hexosaminidase A which should normally convert it
into GM 3 ganglioside. GM3 ganglioside is then converted
by neuraminidase and beta-galactosidase again into glucosylceramide.
This compound is stored in
Gaucher's disease because of a lack of beta-glucocerebrosidase,
which would normally remove the glucose residue to give you ceramide.